Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy

Inclusion Criteria:

• Moderate to severe PsA
• Inadequate response to DMARD therapy
• Corticosteroid stable dose <=10 mg QD
• DMARDs must have been taken for 3 months and stable dose for 4 weeks
• MTX maximum dose = <=30 mg/week
• Active chronic plaque PS or documented history of chronic plaque PS

Exclusion Criteria:

• No other active skin disease